Skip to main navigation Skip to search Skip to main content

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

  • Saranya Sridhar*
  • , Arnel Joaquin
  • , Matthew I. Bonaparte
  • , Agustin Bueso
  • , Anne Laure Chabanon
  • , Aiying Chen
  • , Roman M. Chicz
  • , David Diemert
  • , Brandon J. Essink
  • , Bo Fu
  • , Nicole A. Grunenberg
  • , Helene Janosczyk
  • , Michael C. Keefer
  • , Doris M. Rivera M
  • , Ya Meng
  • , Nelson L. Michael
  • , Sonal S. Munsiff
  • , Onyema Ogbuagu
  • , Vanessa N. Raabe
  • , Randall Severance
    • Enrique Rivas, Natalya Romanyak, Nadine G. Rouphael, Lode Schuerman, Lawrence D. Sher, Stephen R. Walsh, Judith White, Dalia von Barbier, Guy de Bruyn, Richard Canter, Marie Helene Grillet, Maryam Keshtkar-Jahromi, Marguerite Koutsoukos, Denise Lopez, Roger Masotti, Sandra Mendoza, Catherine Moreau, Maria Angeles Ceregido, Shelly Ramirez, Ansoyta Said, Fernanda Tavares-Da-Silva, Jiayuan Shi, Tina Tong, John Treanor, Carlos A. Diazgranados, Stephen Savarino
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology